Medicure (TSXV:MPH) Loans Receivable: C$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:MPH Medicure Inc TSXV:MPH
62 GF Score
Price C$1.04
GF Value C$1.56
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Medicure Loans Receivable?

Medicure TSXV:MPH 62 Loans Receivable is C$0.00 Mil as of Mar. 2026. GuruFocus rates TSXV:MPH with a GF Score™ of 62/100 and a GF Value™ of C$1.56 (Possible Value Trap). The stock has 4 warning signs investors should review.

Medicure's Loans Receivable for the quarter that ended in Mar. 2026 was C$0.00 Mil.

Medicure Loans Receivable Historical Data

* Premium members only.

The historical data trend for Medicure's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicure Loans Receivable Chart

Medicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medicure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:MPH
62GF Score
Medicure Inc TSXV:MPH
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicure Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of C$0.00 Mil mean?
Medicure (TSXV:MPH) has a Loans Receivable of C$0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Medicure and its competitors.
Is Medicure's Loans Receivable too high?
Medicure's current Loans Receivable is C$0.00 Mil. Overall, Medicure has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicure's Loans Receivable compare to ZTS?
Medicure's Loans Receivable of C$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Medicure and its competitors. Medicure's current Loans Receivable is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Based on GuruFocus' analysis, Medicure (TSXV:MPH) is currently considered Possible Value Trap. The stock's GF Value™ is C$1.56, compared to a current price of C$1.04 — trading 33.3% below its estimated fair value. The current Loans Receivable is C$0.00 Mil. Medicure's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Medicure (TSXV:MPH), the current Loans Receivable is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicure (TSXV:MPH) Overvalued in 2026?

Based on GuruFocus' analysis, Medicure stock appears to be undervalued. The current stock price of C$1.04 is trading 33.3% below its estimated GF Value™ of C$1.56. GuruFocus considers Medicure to be Possible Value Trap.

Key valuation signals for TSXV:MPH:

  • Loans Receivable: C$0.00 Mil
  • GF Value™: C$1.56 vs. price of C$1.04 (33.3% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the TSXV:MPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicure Business Description

Other Exchanges MCUJF:USA
Address 1250 Waverley Street, No. 2, Winnipeg, MB, CAN, R3T 6C6
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
62GF Score

Get the complete analysis for TSXV:MPH

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.04
Price
C$1.56
GF Value